Euro vs US Dollar

Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

Registrieren

TNGX Tango Therapeutics Inc

2,85

0,07 (2,52%)

18 Jan 2025 - Geschlossen

Verzögert um 15 Minuten

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Tango Therapeutics (NASDAQ:TNGX)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Click Here for more Tango Therapeutics Charts.

Tango Therapeutics (NASDAQ:TNGX)
Historical Stock Chart
Von Jan 2024 bis Jan 2025

Click Here for more Tango Therapeutics Charts.

News Tango Therapeutics Inc

Form 8-K - Current report
Montag 13 Januar 2025 (1 Woche vor) • Edgar (US Regulatory)

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Donnerstag 2 Januar 2025 (3 Wochen vor) • Edgar (US Regulatory)

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dienstag 3 Dezember 2024 (2 Monate vor) • Business Wire

Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Mittwoch 27 November 2024 (2 Monate vor) • Business Wire

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Mittwoch 20 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 19 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Freitag 8 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Donnerstag 7 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mittwoch 6 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Mittwoch 6 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
Mittwoch 6 November 2024 (2 Monate vor) • Business Wire

Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program
Mittwoch 6 November 2024 (2 Monate vor) • Business Wire

Weitere Tango Therapeutics Inc News-Artikel

Exchange Traded Fund Ubs...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen